Back HCV Treatment

AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence

A 3-drug combination of direct-acting antivirals developed by AbbVie cured hepatitis C genotype 1 infection in 96% of transplant recipients with recurrent hepatitis C virus (HCV) in a small Phase 2 study reported last week at the 49th EASL International Liver Congress (EASL 2014) in London.

alt

Read more: